For years, many medical device manufacturers approached U.S. Food and Drug Administration (FDA) inspections through a familiar lens: Prepare documents, review subsystem requirements, rehearse likely questions, and demonstrate compliance against a known framework.

ISO has set its focus on revising three key management system standards this year. It started with ISO 14001, which covers environmental management and was published on April 15, 2026. ISO 9001 for quality management will follow in the fall.

A line operator in a chemical packaging plant notices a torque inconsistency on a capping head.

Audit week has a way of revealing gaps that stay invisible during normal operations. Your methods are sound, and your data look clean. Then the assessor asks for the calibration certificate on the torque wrench used last Tuesday, and someone heads off to find it.

In the larger organizations I worked for as a quality leader, supplier auditing was almost always calendar-driven.

FDA inspectors don’t just check your records. They bring their own thermometer.

When a training matrix is built and managed correctly, it’s the backbone of compliance. It ensures that every employee knows how to perform their job and creates the traceability auditors love to see.

A CAPA investigator opens an AI-enabled quality management system and asks for potential root causes. The system produces several plausible explanations, summarizes similar historical events, and recommends corrective actions.

ISO 9001:2026 is in its final development stage. The final draft international standard (FDIS) has been submitted for ballot, and publication is expected in September 2026.

The U.S. Food and Drug Administration’s April 2, 2026, warning letter to Purolea Cosmetics Lab is making the rounds, mostly under some version of “FDA cracks down on AI in manufacturing.”